Sign in →

Test ID: CARPB Carbamazepine Hypersensitivity Pharmacogenomics, Blood

Useful For

Identifying individuals with increased risk of risk of carbamazepine-associated cutaneous adverse reactions


Identifying individuals who may be at increased risk of cutaneous adverse reactions when treated with alternative medications to carbamazepine including phenytoin, fosphenytoin, oxcarbazepine, eslicarbazepine acetate, and lamotrigine

Method Name

Qualitative Allele-Specific Real-Time Polymerase Chain Reaction (PCR)

Reporting Name

Carbamazepine PGx Panel, B

Specimen Type

Whole Blood EDTA

Specimen Required

Multiple whole blood EDTA genotype tests can be performed on a single specimen after a single extraction. See Multiple Whole Blood EDTA Genotype Tests in Special Instructions for a list of tests that can be ordered together.


Container/Tube: Lavender top (EDTA)

Specimen Volume: 3 mL

Collection Instructions: Send specimen in original tube.

Specimen Minimum Volume

0.35 mL

Specimen Stability Information

Specimen Type Temperature Time
Whole Blood EDTA Ambient (preferred)

Clinical Information

Carbamazepine is sometimes prescribed for the treatment of epilepsy, as well as trigeminal neuralgia and bipolar disorder. A minority of carbamazepine-treated persons have cutaneous adverse reactions that vary in prevalence and severity, with some forms associated with substantial morbidity and mortality. More severe reactions, such as the hypersensitivity syndrome, are associated with mortality of up to 10% and include symptoms such as rash, fever, eosinophilia, hepatitis, and nephritis. The most severe reactions, such as the Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), are characterized by a blistering rash affecting a variable percentage of the body-surface area. TEN is the rarest of these phenotypes and is associated with mortality of up to 30%. According to the FDA-approved label for carbamazepine, the estimated incidence of SJS-TEN is 1 to 6 cases in 10,000 persons of European ancestry who are exposed to the drug. The rate of SJS-TEN as a result of carbamazepine exposure is about 10 times higher in some Asian countries.


Clinical studies have demonstrated associations between some human leukocyte antigen (HLA) genotypes and drug-associated cutaneous adverse reactions. The presence of the HLA-B*15:02 allele varies throughout Asia: 10% to 15% frequency in Chinese, 2% to 4% frequency in Southeast Asians, including Indians, and <1% frequency in Japanese and Koreans.


The HLA-A*31:01 allele, which has a prevalence of 2% to 5% in Northern European populations, has been significantly associated with drug-associated cutaneous adverse reactions. In the absence of HLA-A*31:01, the risk for drug-associated cutaneous adverse reactions is 3.8%, but in the presence of this allele, the risk increases to 26%.  


The FDA-approved label for carbamazepine states that the screening of patients in genetically at-risk populations (ie, patients of Asian descent) for the presence of the HLA-B*15:02 allele should be carried out prior to initiating treatment with carbamazepine. The FDA-approved label also notes the association of HLA-A*31:01 allele with drug-associated cutaneous adverse reactions regardless of ethnicity but does not specifically mandate screening of patients. For patients who are HLA-B*15:02 and HLA-A*31:01 positive, oxcarbazepine, phenytoin, fosphenytoin, eslicarbazepine acetate, and lamotrigine may also be associated with drug-associated cutaneous adverse reactions so these medications may need to be avoided as well.

Reference Values

An interpretive report will be provided.


The presence of the HLA-B*15:02 and/or HLA-A*31:01 allele confers increased risk for hypersensitivity to carbamazepine.

Clinical Reference

1. Leckband SG, Kelsoe JR, Dunnenberger HM, et al: Clinical Pharmacogenetics Implementation Consortium guideline for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013;94(3):324-328

2. Caudle KE, Rettie AE, Whirl-Carrillo M, et al: Clinical pharmacogenetics implementation consortium guidelines for CYP2C9 and HLA-B genotypes and phenytoin dosing. Clin Pharacol Ther. 2014;96(5):542-548

3. McCormack M, Alfirevic A, Bourgeois S, et al: HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011;364:1134-1143

4. Amstutz U, Shear NH, Rieder MJ, et al: Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions. Epilepsia 2014;55:496-506.  

Day(s) and Time(s) Performed

Monday, Thursday

Analytic Time

1 day (not reported Saturday or Sunday)

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

81381 x 2

LOINC Code Information

Test ID Test Order Name Order LOINC Value
CARPB Carbamazepine PGx Panel, B In Process


Result ID Test Result Name Result LOINC Value
37296 HLA-A3101 Genotype 79712-6
37297 HLA-B1502 Genotype 57979-7
37298 Carbamazepine PGx Panel Phenotype In Process
37299 Carbamazepine PGx Panel Interpretation In Process
37407 Reviewed by 18771-6


If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

Neurology Specialty Testing Client Test Request (T732) (

Pharmacogenomics Test Request Form (T797) (

Mayo Medical Laboratories | Genetics and Pharmacogenomics Catalog Additional Information: